Q-omics provides the consensus-scored SMAD1-AS2 profile across patient tissues and cancer cell-line models. SMAD1-AS2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, SMAD1-AS2 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, SMAD1-AS2 RNA expression shows 8,165 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight CHOL, STAD, and CCRCC as cancer lineages where SMAD1-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMAD1-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMAD1-AS2 survival associations across molecular data types. SMAD1-AS2 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMAD1-AS2 RNA expression–survival associations across cancer types. High SMAD1-AS2 expression shows unfavorable associations in CHOL, LUSC, THCA, READ, UCEC and ACC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for SMAD1-AS2 RNA expression.
This table summarizes SMAD1-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SMAD1-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMAD1-AS2 shows lower tumor expression in BRCA and higher tumor expression in STAD. The STAD box plot shows higher SMAD1-AS2 RNA expression in tumor versus normal tissue (log2 FC = +0.077, t-test p = .026).
This table shows molecular features associated with SMAD1-AS2 in patient tissues and cancer cell lines. In patient samples, SMAD1-AS2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
